The prognosis of head and neck squamous cell carcinoma (HNSCC) is largely based on disease stage. Despite improvements in treatment, recurrence rates are still considered high. Currently, disease progression or regression after curative treatment is monitored by clinical evaluation combined with flexible endoscopy and/or imaging. However, specificity of imaging is low due to the posttreatment effects. Detection of circulating tumor DNA (ctDNA) from blood samples of HNSCC patients is a minimally invasive technique that could lead to an earlier detection of recurrence. In addition, digital droplet PCR (ddPCR) could be used to sensitively detect these mutational targets. Future study on ctDNA using ddPCR in blood samples of HNSCC patients is recommended during the follow-up stage to detect recurrences in a timely manner.

Keywords:
Head and neck cancer, Posttreatment surveillance, Liquid biopsy, Droplet digital polymerase chain reaction
1.
Braakhuis BJ, Leemans CR, Visser O: Incidence and survival trends of head and neck squamous cell carcinoma in The Netherlands between 1989 and 2011. Oral Oncol 2014;50:670-675.
2.
Ho AS, Kraus DH, Ganly I, Lee NY, Shah JP, Morris LG: Decision making in the management of recurrent head and neck cancer. Head Neck 2014;36:144-151.
3.
de Bree R, van der Putten L, Brouwer J, Castelijns JA, Hoekstra OS, Leemans CR: Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncol 2009;45:386-393.
4.
Isles MG, McConkey C, Mehanna HM: A systematic review and meta-analysis of the role of positron emission tomography in the follow-up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33:210-222.
5.
da Silva BF, Gurgel APAD, Neto MADL, de Azevedo DA, de Freitas AC, Neto JDS, Silva LAF: Circulating cell-free DNA in serum as a biomarker of colorectal cancer. J Clin Pathol 2013;66:775-778.
6.
Hao TB, Shi W, Shen XJ, Qi J, Wu XH, Wu Y, Tang YY, Ju SQ: Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. Br J Cancer 2014;111:1482-1489.
7.
Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS: Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006;24:4270-4276.
8.
Qiu MT, Wang J, Xu YT, Ding XX, Li M, Jiang F, Xu L, Yin R: Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidem Biomar 2015;24:206-212.
9.
Leemans CR, Braakhuis BJ, Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
10.
van Kempen PM, Noorlag R, Braunius WW, Stegeman I, Willems SM, Grolman W: Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 2014;9:194-203.
11.
O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA: Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012;48:1191-1201.
12.
Chung CH, Guthrie VB, Masica DL, Tokheim C, Kang H, Richmon J, Agrawal N, Fakhry C, Quon H, Subramaniam RM, Zuo Z, Seiwert T, Chalmers ZR, Frampton GM, Ali SM, Yelensky R, Stephens PJ, Miller VA, Karchin R, Bishop JA: Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. Ann Oncol 2015;26:1216-1223.
13.
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-1157.
14.
Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, et al: The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-1160.
15.
Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, Schuhmann A, Bosch FX: Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993;53:4189-4196.
16.
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003;63:1727-1730.
17.
Braakhuis BJ, Leemans CR, Brakenhoff RH: A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med 2004;33:317-322.
18.
Graveland AP, Golusinski PJ, Buijze M, Douma R, Sons N, Kuik DJ, Bloemena E, Leemans CR, Brakenhoff RH, Braakhuis BJM: Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int J Cancer 2011;128:1852-1859.
19.
Graveland AP, Bremmer JF, de Maaker M, Brink A, Cobussen P, Zwart M, Braakhuis BJ, Bloemena E, van der Waal I, Leemans CR, Brakenhoff RH: Molecular screening of oral precancer. Oral Oncol 2013;49:1129-1135.
20.
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 1996;56:2488-2492.
21.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
22.
Gagan J, Van Allen EM: Next-generation sequencing to guide cancer therapy. Genome Med 2015;7:80.
23.
Diaz LA Jr, Bardelli A: Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-586.
24.
Mandel P, Metais P: Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948;142:241-243.
25.
Alix-Panabieres C, Schwarzenbach H, Pantel K: Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012;63:199-215.
26.
Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008;8:329-340.
27.
Wollenberg B, Walz A, Kolbow K, Pauli C, Chaubal S, Andratschke M: Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN. Onkologie 2004;27:358-362.
28.
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A: Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-484.
29.
Lui YY, Dennis YM: Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. Clin Chem Lab Med 2002;40:962-968.
30.
Lo YMD, Rainer TH, Chan LYS, Hjelm NM, Cocks RA: Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319-323.
31.
Chen Z, Fadiel A, Naftolin F, Eichenbaum KD, Xia Y: Circulation DNA: biological implications for cancer metastasis and immunology. Med Hypotheses 2005;65:956-961.
32.
Hamana K, Uzawa K, Ogawara K, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Br J Cancer 2005;92:2181-2184.
33.
Ignatiadis M, Lee M, Jeffrey SS: Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res 2015;21:4786-4800.
34.
Thierry AR, Mouliere F, Gongora C, Ollier J, Robert B, Ychou M, Del Rio M, Molina F: Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010;38:6159-6175.
35.
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, Kinzler KW, Vogelstein B, Diaz LA: Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-990.
36.
Fleischhacker M, Schmidt B: Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta 2007;1775:181-232.
37.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra224.
38.
Bidard FC, Peeters DJ, Fehm T, Nole F, Gisbert-Criado R, et al: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014;15:406-414.
39.
Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME: Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010;56:1492-1495.
40.
Ignatiadis M, Dawson SJ: Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? Ann Oncol 2014;25:2304-2313.
41.
Mockelmann N, Laban S, Pantel K, Knecht R: Circulating tumor cells in head and neck cancer: clinical impact in diagnosis and follow-up. Eur Arch Otorhinolaryngol 2014;271:15-21.
42.
Pantel K, Speicher MR: The biology of circulating tumor cells. Oncogene 2016;35:1216-1224.
43.
Tabatabaeifar S, Kruse TA, Thomassen M, Larsen MJ, Sorensen JA: Use of next-generation sequencing in head and neck squamous cell carcinomas: a review. Oral Oncol 2014;50:1035-1040.
44.
Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, Shukla M, Chesnick B, Kadan M, Papp E, Galens KG, Murphy D, Zhang T, Kann L, Sausen M, Angiuoli SV, Diaz LA Jr, Velculescu VE: Personalized genomic analyses for cancer mutation discovery and interpretation. Sci Transl Med 2015;7:283ra253.
45.
Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, et al: High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Analytical Chemistry 2011;83:8604-8610.
46.
Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, Dahlgren M, Schulz R, Grabau D, van Westen D, Ferno M, Ingvar C, Rose C, Bendahl PO, Ryden L, Borg A, Gruvberger-Saal SK, Jernstrom H, Saal LH: Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 2015;7:1034-1047.
47.
Reinert T, Scholer LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, Lamy P, Kannerup AS, Mortensen FV, Stribolt K, Hamilton-Dutoit S, Nielsen HJ, Laurberg S, Pallisgaard N, Pedersen JS, Orntoft TF, Andersen CL: Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2016;65:625-634.
48.
Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Janne PA: A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial. Clin Cancer Res 2016, E-pub ahead of print.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.